GNLX

Genelux Corp

Sep 18 • 02:44PM ET

4.01

+0.10 2.43 %

Healthcare • Biotechnology • USA • NASD

Peers: LLY VRTX MRNA REGN PFE NVS GILD BMY AMGN BIIB

| Held by: VTI VXF IWC AVSC DFAC RFLR BTEC CHNA

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	14.40%	Shs Outstand	37.33M	Perf Week	9.73%
Market Cap	151.28M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-0.49%	Shs Float	32.34M	Perf Month	16.76%
Enterprise Value	125.02M	PEG	-	EPS next Q	-0.22	Inst Own	19.57%	Short Float	6.54%	Perf Quarter	37.16%
Income	-30.39M	P/S	-	EPS this Y	8.63%	Inst Trans	1.48%	Short Ratio	16.29	Perf Half Y	0.13%
Sales	0.00M	P/B	6.26	EPS next Y	-10.60%	ROA	-78.50%	Short Interest	2.12M	Perf YTD	69.70%
Book/sh	0.64	P/C	5.41	EPS next 5Y	5.57%	ROE	-98.72%	52W High	5.89 -31.95%	Perf Year	57.68%
Cash/sh	0.74	P/FCF	-	EPS past 3/5Y	-11.05% -14.03%	ROIC	-120.32%	52W Low	1.95 105.38%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.94% 6.84%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	11.41%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.18	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	61.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.18	EPS Q/Q	11.29%	SMA20	9.45%	Beta	-0.33	Target Price	18.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	14.44%	Rel Volume	1.07	Prev Close	3.91
Employees	24	LT Debt/Eq	0.06	Earnings	Aug 07 AMC	SMA200	25.60%	Avg Volume	129.89K	Price	4.01
IPO	Jan 26, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.41% -	Trades		Volume	112,738	Change	2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-24	Initiated	Guggenheim	Buy	$8
Aug-28-24	Initiated	ROTH MKM	Buy	$10
Nov-27-23	Initiated	H.C. Wainwright	Buy	$35
Sep-12-23	Initiated	Maxim Group	Buy	$40
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy	$10

Sep-02-25 04:01PM	Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-07-25 04:20PM	Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -6.96% -5.69%
Jul-07-25 07:00AM	Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development (GlobeNewswire)
Jun-02-25 12:00PM	Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know (Zacks)
May-06-25 04:10PM	Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -7.17%
04:05PM	Loading…
May-01-25 04:05PM	Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire) -9.85% +8.45%
Apr-18-25 09:40AM	Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 04:10PM	Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -12.34%
09:35AM	Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Mar-25-25 08:31AM	Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.60%
08:30AM	Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease (GlobeNewswire)
08:30AM	Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer (GlobeNewswire)
Mar-02-25 09:39AM	Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-03-25 06:45AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) -10.63%
Dec-13-24 07:01AM	Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright (GlobeNewswire) -7.54%
09:50AM	Loading…
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -19.73%
Nov-14-24 04:05PM	Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Nov-06-24 04:01PM	Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-25-24 01:01PM	Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp (GuruFocus.com)
Oct-23-24 11:27AM	Genelux doses first subject in Phase II trial of NSCLC treatment (Clinical Trials Arena)
Oct-22-24 04:01PM	Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-09-24 04:15PM	Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.94%
Aug-14-24 09:54PM	GNLX Stock Earnings: Genelux Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-12-24 05:16PM	Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds (Insider Monkey) -6.57%
Jul-30-24 07:00AM	Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 (GlobeNewswire)
May-24-24 08:00AM	Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -43.04%
May-23-24 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire) -5.35%
May-09-24 11:53PM	GNLX Stock Earnings: Genelux Misses EPS for Q1 2024 (InvestorPlace) +6.07%
04:25PM	Loading…
04:25PM	Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Apr-26-24 09:35AM	Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-23-24 09:35AM	Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-05-24 09:35AM	After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) (Zacks)
Apr-04-24 12:00PM	All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy (Zacks)
Apr-02-24 07:52AM	GNLX Stock Earnings: Genelux Misses EPS for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -18.51%
Dec-15-23 03:01PM	Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX) (GuruFocus.com) -13.23%
Nov-27-23 07:00AM	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer (GlobeNewswire)
Nov-14-23 05:50PM	Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire) -7.61%
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-19-23 03:01PM	Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX) (GuruFocus.com) +8.04%
Sep-15-23 03:03PM	Director John Smither Sells 900 Shares of Genelux Corp (GNLX) (GuruFocus.com)
Sep-14-23 01:21PM	10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX) (GuruFocus.com)
07:00AM	Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.69%
Aug-28-23 07:00AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) +11.01%
Aug-14-23 07:00AM	Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-02-23 04:00PM	Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023 (GlobeNewswire) +5.52%
01:08AM	10 Recent IPOs in 2023 to Consider (Insider Monkey)
Jul-28-23 10:54AM	Why Shares of Genelux Climbed This Week (Motley Fool) -9.38%
Jul-20-23 04:45PM	Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires (GlobeNewswire) -10.85% -15.77%
Jul-10-23 07:00AM	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology (GlobeNewswire)
Jun-29-23 07:00AM	Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire)
Jun-22-23 07:00AM	Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 (GlobeNewswire) -7.05%
Jun-12-23 07:00AM	Genelux Corporation Announces $18 Million Private Placement (GlobeNewswire) +7.58%
Jun-01-23 05:19PM	Why Shares of Genelux Corporation Jumped This Week (Motley Fool) +6.62%
May-25-23 04:01PM	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology (GlobeNewswire) +6.62%
May-15-23 07:00AM	Genelux Corporation Announces $33 Million Private Placement (GlobeNewswire) -9.06%
Mar-23-23 07:00AM	Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 (GlobeNewswire)
Jan-25-23 09:00PM	Genelux Corporation Announces Pricing of Initial Public Offering (GlobeNewswire)

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ryder Sean	General Counsel	May 12 '25	Sale	2.92	4,475	13,067	47,621	May 13 05:05 PM
Zindrick Thomas	President and CEO	May 12 '25	Sale	2.92	10,764	31,431	191,447	May 13 05:05 PM
Yu Yong	VP, Clinical Trial Operations	May 12 '25	Sale	2.92	5,579	16,291	47,640	May 13 05:05 PM
Cappello Joseph	VP, Pharmaceutical Development	May 12 '25	Sale	2.92	4,737	13,832	52,266	May 13 05:05 PM
Smalling Ralph	Head of Regulatory	May 12 '25	Sale	2.92	1,259	3,676	34,760	May 13 05:05 PM
Tyree James L	Director	Dec 30 '24	Sale	2.46	3,460	8,512	45,791	Dec 30 07:48 PM
JAMES L TYREE	Director	Dec 30 '24	Proposed Sale	2.46	3,460	8,512		Dec 30 04:10 PM
Zindrick Thomas	President and CEO	Dec 16 '24	Sale	2.34	14,315	33,497	37,372	Dec 18 04:35 PM
Zak Lourie S.	Chief Financial Officer	Dec 16 '24	Sale	2.34	2,103	4,921	40,802	Dec 18 04:35 PM
Smalling Ralph	Head of Regulatory	Dec 16 '24	Sale	2.34	2,510	5,873	16,322	Dec 18 04:35 PM
Cappello Joseph	VP, Pharmaceutical Development	Dec 16 '24	Sale	2.34	6,300	14,742	14,653	Dec 18 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNLX

Genelux Corp

Upgrade your FINVIZ experience